Niagen Bioscience

What Niagen Bioscience does

Niagen Bioscience (NASDAQ: NAGE), founded in 1999 and headquartered in Los Angeles, is a vertically integrated NAD+ science company built around its patented nicotinamide riboside chloride ingredient (Niagen). The company holds what it describes as the only U.S. Pharmacopeia monograph among NAD+ precursors, supported by FDA NDI notifications, GRAS status, Health Canada, Australian TGA, and EFSA approvals, and a portfolio of 60+ patents including US 12,558,367 covering IV and injectable NR formulations through approximately 2044. The business spans consumer oral supplements (Tru Niagen and the November 2025 Tru Niagen Beauty launch), pharmaceutical-grade IV and injectable therapies (Niagen Plus, distributed through 1,200+ clinical partners and a newly launched May 2026 telehealth platform dispensing at-home injection kits), topical skincare (March 2026's Niagen NanoCloud waterless sachets), and B2B ingredient licensing to manufacturers and brand partners.

The company operates four reinforcing go-to-market motions: DTC e-commerce with subscription and HSA/FSA eligibility (via Truemed), a clinical channel of 1,200+ healthcare, wellness, and longevity clinics plus 80+ OneSpaWorld cruise ship medi-spas served by dual 503B compounding partners (Wells Pharmacy of Houston and Olympia Pharmaceuticals), clinician-directed telehealth for prescription-only injectables, and global B2B licensing supported by the Niagen Research Program's 300+ research collaborations across 34 countries and 500+ publications. FY2025 net sales reached $129.4M (up 30% YoY) with net income of $17.4M, adjusted EBITDA of $20.4M, and 64.3% gross margin; the company exited FY2025 with $64.8M cash and zero debt, and guided 10-15% growth for 2026. The divestiture of ChromaDex Reference Standards to LGC in February 2026 reflects a deliberate narrowing of scope toward NAD+ therapeutics and longevity.

Name

Niagen Bioscience

Legal name

ChromaDex, Inc.

Website

https://niagenbioscience.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Niagen Bioscience (NASDAQ: NAGE) is a vertically integrated NAD+ science company that develops, patents, and commercializes nicotinamide riboside (Niagen) via consumer supplements, clinical IV and injectable therapies, and B2B ingredient licensing across more than 1,200 clinics and a new telehealth channel.

Ownership category

akta.pro rank

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Marketing or Sales, Personnel, Supply Chain

Revenue model

1. Consumer Supplement Sales (Tru Niagen): Direct-to-consumer e-commerce sales of Tru Niagen oral NAD+ supplements through truniagen.com. The brand is positioned as America's trusted NAD-boosting supplement with clinically proven daily support. Sales driven by subscription model with flexible serving options and superior bioavailability.
2. Clinical/Pharmaceutical Therapy (Niagen Plus): Revenue from pharmaceutical-grade Niagen IV and injectable therapies distributed through 1,200+ healthcare clinics, telehealth platform, and cruise ship medi-spas. Products include prescription-only subcutaneous injection kits and intravenous formulations dispensed through licensed 503A/503B compounding pharmacies.
3. Skincare Products (Niagen NanoCloud): Sales of Niagen NanoCloud topical skincare sachets launched March 2026 at $59 per 30-sachet unit. Waterless powder format extends NAD+ science into cosmetics market, generating consumer insights for future topical product development.
4. B2B Ingredient Licensing: Revenue from licensing Niagen ingredient to manufacturers, healthcare innovators, and brands for incorporation into their products. Company collaborates with global partners to push boundaries of NAD+ science through research partnerships and ingredient supply agreements.
5. Niagen Beauty Supplement (Tru Niagen Beauty): Sales of Tru Niagen Beauty, launched November 2025, combining NAD+ support with skin and hair ingredients including astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E. Targets cellular health and beauty from within.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Niagen Bioscience develops, manufactures, and commercializes its patented Niagen (nicotinamide riboside chloride) ingredient across consumer dietary supplements (Tru Niagen, Tru Niagen Beauty), pharmaceutical-grade clinical therapies (Niagen Plus IV and injectables), topical skincare (Niagen NanoCloud), and B2B ingredient licensing to manufacturers. The company operates a direct-to-consumer e-commerce platform, a clinician-directed telehealth platform for prescription at-home injection kits, and a network of over 1,200 clinics.

Product overview

Niagen Bioscience operates two primary brand lines powered by its patented Niagen nicotinamide riboside ingredient: Tru Niagen (consumer dietary supplements for daily NAD+ boosting) and Niagen Plus (pharmaceutical-grade IV and injectable NAD+ therapies through healthcare providers). Tru Niagen encompasses oral supplements including the original Tru Niagen, Tru Niagen Beauty (NAD-focused skincare supplement), and related products. Niagen Plus includes clinical IV therapies at over 1,200 clinics plus the new telehealth-enabled at-home injection platform. The company also recently launched Niagen NanoCloud through its Skincare Innovation Lab—a topical skincare entry using waterless sachet technology. The company sponsors the Niagen Research Program (formerly CERP) supporting external NAD+ research globally. Revenue streams include direct-to-consumer e-commerce (Tru Niagen), B2B ingredient sales, and clinical/ telehealth channels (Niagen Plus).

Differentiator

Problem solved

Functional benefit

Brands

• Tru Niagen®: Premium food-grade oral NAD+ supplement brand for daily cellular vitality support.
• Niagen® Plus
• Niagen NanoCloud™

Products and services

• Tru Niagen Premium food-grade oral NAD+ supplement containing patented nicotinamide riboside (Niagen), clinically proven to boost NAD+ levels by up to 150% and support cellular energy, repair, and healthy aging. Available in various serving sizes via subscription e-commerce at truniagen.com. Targeted at health-conscious adult consumers.
• Niagen Plus Pharmaceutical-grade NAD+ enhancement therapy delivered through healthcare providers and a new telehealth platform. Includes Niagen IV (intravenous) and injectable formulations available at over 1,200 clinics nationwide plus at-home subcutaneous injection kits dispensed by licensed 503A/503B pharmacies. Targeted at medical patients and clinical operators.
• Tru Niagen Beauty NAD-focused beauty supplement combining Niagen with astaxanthin, hyaluronic acid, grape seed extract, biotin, and vitamin E to support skin elasticity, hair strength, and nail health from within. Sold via subscription through truniagen.com. Targeted at premium beauty and longevity consumers.
• Niagen NanoCloud Waterless topical skincare product in sachet format delivering patented Niagen nicotinamide riboside. Protects NR from degradation until point of use, solving instability challenges common in NAD+ skincare formulations. Dermatologist-tested. Targeted at premium anti-aging skincare consumers.
• Niagen (Nicotinamide Riboside Chloride) Ingredient B2B patented nicotinamide riboside chloride (NRCl) ingredient licensed to manufacturers, healthcare innovators, and brand partners for incorporation into consumer health, nutraceutical, and pharmaceutical products. FDA NDI notified (2015, 2018), GRAS status (2016), USP monograph published. Targeted at consumer health manufacturers and brand partners globally.

Quantifiable outcome

• Increases NAD+ levels by up to 150%
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

13 partnerships are on record, tiered strategic, core and minor.

• Taiki (Korean manufacturer)strategicOEM/ Whitelabel/ Licensing Partner · 4 May 2026Partnership with Taiki, a leading Korean manufacturer specializing in innovative delivery formats, for production of Niagen NanoCloud sachets. Waterless powder format developed in partnership protects Niagen until the moment of use, solving stability challenge that limits traditional NAD+ skincare products.
• Olympia PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 28 April 2026Partnership with Olympia Pharmaceuticals, a U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen for Niagen Plus intravenous and injectable products. Addition diversifies Niagen Bioscience's 503B compounding network beyond existing partner Wells Pharma of Houston, expanding supply chain capabilities to support growth across clinic footprint nationwide. Collaboration meets growing demand for Niagen IV and injections in healthy aging and longevity market.
• OneSpaWorld HoldingscoreChannel Partner/ Reseller/ Distributor · 31 March 2026Partnership to offer pharmaceutical-grade Niagen IV at over 80 Medi-Spa clinics onboard high-end cruise ships, marking the company's first cruise ship clinic partnership. Collaboration extends Niagen's clinical network to new premium distribution point targeting on-vacation consumers seeking wellness experiences, with deployment aligned to ship-specific operations and regulatory requirements. Rollout expected to meaningfully expand OneSpaWorld's fleet footprint while providing scalable pathway for Niagen Plus to reach new consumers.
• LGC (VHG Labs/LGC Standards)minorOthers · 24 February 2026Sale of ChromaDex Reference Standards business to LGC in all-cash transaction. Deal enables Niagen Bioscience to exit non-core activities and focus on NAD+ science. LGC Standards, a division of LGC Group, acquired analytical reference standards and services business to expand North American commercial reach and enhance reference materials portfolio for pharmaceutical, laboratory, and food production customers.
• LGC LimitedminorOthers · 24 February 2026LGC Limited acquired ChromaDex Reference Standards from Niagen Bioscience in February 2026, strengthening LGC's ability to serve pharmaceutical customers, testing laboratories, and food producers while expanding North American commercial reach.
• University of CopenhagenstrategicStrategic or Co-development Partner · 9 February 2026Premiere sponsor of inaugural 'NAD for Health: Opportunities & Challenges' scientific conference hosted by University of Copenhagen (March 23-25, 2026). Conference focuses on NAD metabolism research, aging biology, and translational frameworks, bringing together researchers, clinicians, and industry partners. Dr. Jonas Treebak and Dr. Vilhelm Bohr organizing the event, with Dr. Bohr serving on Niagen Bioscience's Scientific Advisory Board.
• TruemedstrategicChannel Partner/ Reseller/ Distributor · 29 January 2026Partnership enabling qualified customers to purchase Tru Niagen using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds. Truemed provides a Letter of Medical Necessity for eligible buyers, expanding accessibility of the NAD+ supplement to consumers with pre-tax healthcare accounts.
• Queen's University BelfastcoreTechnology or Integration · 22 December 2025Acquisition of comprehensive patent portfolio covering nicotinamide riboside (NR) from Queen's University Belfast. Transaction consolidates Niagen Bioscience's leadership position in NAD+ precursor intellectual property, covering manufacturing, composition, and use rights globally. Grant includes various NR salt forms and derivatives, making company sole owner of critical IP in NAD+ industry.
• Mayo ClinicstrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from Mayo Clinic among 300+ global research collaborations supporting NAD+ science. Mayo Clinic researchers participate in investigator-initiated studies using Niagen materials provided through Material Transfer Agreements.
• National Institutes of Health (NIH)strategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from National Institutes of Health among 300+ global research agreements. NIH researchers participate in investigator-initiated and third-party funded studies advancing NAD+ biology understanding.
• Harvard UniversitystrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from Harvard University. Harvard researchers contribute to peer-reviewed publications on NR and NAD+ biology through investigator-initiated studies.
• Cambridge UniversitystrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from Cambridge University among leading research institutions supporting NAD+ science and clinical studies.
• MITstrategicStrategic or Co-development PartnerResearch collaboration through Niagen Research Program with investigators from MIT contributing to NAD+ precursor research and clinical studies.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Designs for Health: Designs for Health is a practitioner-grade supplement company with a clinical channel model very similar to Niagen's 1,200+ clinic distribution network. Comparable on professional channel distribution, premium quality positioning, and cellular health product focus.
• Momentous: Momentous is a premium longevity and human performance supplement brand with scientific advisory ties (e.g., Dr. Andrew Huberman) and an emphasis on cellular health, mitochondrial function, and NAD+ support — a peer in the premium longevity DTC category.
• Elysium Health: Elysium Health sells Basis, a direct NAD+ precursor supplement combining nicotinamide riboside with pterostilbene, targeting the same cellular aging and longevity use cases as Tru Niagen. It is the most direct head-to-head competitor in the consumer NAD+ category.
• Pure Encapsulations: Pure Encapsulations is a practitioner-channel premium supplement brand owned by Nestlé Health Science. It serves healthcare practitioners with hypoallergenic, science-backed formulations — comparable to Niagen's clinical channel strategy and quality positioning.
• Life Extension: Life Extension is a long-established direct-to-consumer longevity supplement brand with a broad catalog including NAD+ and cellular health products. It targets the same health-conscious, anti-aging consumer demographic and competes directly on subscription DTC channels.
• Thorne HealthTech: Thorne is a premium, practitioner-grade supplement brand with a strong scientific positioning, NSF Certified for Sport, and a similar longevity/cellular health focus. Comparable on premium positioning, clinical channel distribution, and science-led brand-building to Niagen's Tru Niagen line.

Emerging players

• Neurohacker Collective: Neurohacker Collective sells Qualia line supplements targeting longevity, cognition, and cellular health. It overlaps on longevity positioning and the science-led premium supplement category, though its core focus is broader nootropic/longevity rather than NAD+ specifically.
• Restore Hyper Wellness: Restore Hyper Wellness is a national franchise of wellness clinics offering IV therapies including NAD+ and has conducted research on Niagen IV tolerability. Comparable as a clinical channel partner and competitor for IV-based NAD+ delivery.
• Codeage: Codeage is a DTC longevity supplement brand with NAD+, NMN, and cellular aging products targeting the same health-conscious consumer. It is a smaller emerging competitor in the direct NAD+ precursor space.
• Jinfiniti Precision Medicine: Jinfiniti offers NAD+ testing and measurement services for consumers and researchers, addressing the same NAD+ science ecosystem. It is adjacent rather than directly competitive but operates in the same NAD+ biology category and serves overlapping consumer/research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/niagenbio

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Subsidiaries1 record

Funding overview

Funding rounds13 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Niagen Bioscience